author-photo

Geraldine Gebhart

Université libre de Bruxelles

22

Papers

547

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P1-19-22: Pearl or the use of FDG positron emission tomography imaging as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.

2020 Hellenic Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

2019 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (34)
HER2-positive breast cancer is lost in translation: time for patient-centered research

2017 Nature Reviews Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (45)
N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89 Zr-Trastuzumab and 18 F-FDG PET imaging

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (7)
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (193)
Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

2015 Molecular Imaging and Biology
Show All
- Source
- Cite
- Save
Citations (7)